QQQ   366.48 (-1.10%)
AAPL   166.23 (-2.10%)
MSFT   303.33 (+0.22%)
FB   319.59 (+0.45%)
GOOGL   2,702.33 (-0.65%)
AMZN   3,125.98 (-1.65%)
TSLA   995.65 (-3.38%)
NVDA   250.67 (-3.23%)
BABA   127.74 (-0.67%)
NIO   28.63 (-3.31%)
AMD   128.27 (-2.77%)
CGC   7.64 (-1.80%)
MU   90.00 (-3.09%)
GE   100.62 (-2.21%)
T   27.28 (-0.11%)
F   22.45 (-7.92%)
DIS   150.11 (-1.42%)
AMC   18.32 (-2.76%)
PFE   53.54 (-1.05%)
ACB   4.86 (-4.89%)
BA   217.08 (-3.52%)
QQQ   366.48 (-1.10%)
AAPL   166.23 (-2.10%)
MSFT   303.33 (+0.22%)
FB   319.59 (+0.45%)
GOOGL   2,702.33 (-0.65%)
AMZN   3,125.98 (-1.65%)
TSLA   995.65 (-3.38%)
NVDA   250.67 (-3.23%)
BABA   127.74 (-0.67%)
NIO   28.63 (-3.31%)
AMD   128.27 (-2.77%)
CGC   7.64 (-1.80%)
MU   90.00 (-3.09%)
GE   100.62 (-2.21%)
T   27.28 (-0.11%)
F   22.45 (-7.92%)
DIS   150.11 (-1.42%)
AMC   18.32 (-2.76%)
PFE   53.54 (-1.05%)
ACB   4.86 (-4.89%)
BA   217.08 (-3.52%)
QQQ   366.48 (-1.10%)
AAPL   166.23 (-2.10%)
MSFT   303.33 (+0.22%)
FB   319.59 (+0.45%)
GOOGL   2,702.33 (-0.65%)
AMZN   3,125.98 (-1.65%)
TSLA   995.65 (-3.38%)
NVDA   250.67 (-3.23%)
BABA   127.74 (-0.67%)
NIO   28.63 (-3.31%)
AMD   128.27 (-2.77%)
CGC   7.64 (-1.80%)
MU   90.00 (-3.09%)
GE   100.62 (-2.21%)
T   27.28 (-0.11%)
F   22.45 (-7.92%)
DIS   150.11 (-1.42%)
AMC   18.32 (-2.76%)
PFE   53.54 (-1.05%)
ACB   4.86 (-4.89%)
BA   217.08 (-3.52%)
QQQ   366.48 (-1.10%)
AAPL   166.23 (-2.10%)
MSFT   303.33 (+0.22%)
FB   319.59 (+0.45%)
GOOGL   2,702.33 (-0.65%)
AMZN   3,125.98 (-1.65%)
TSLA   995.65 (-3.38%)
NVDA   250.67 (-3.23%)
BABA   127.74 (-0.67%)
NIO   28.63 (-3.31%)
AMD   128.27 (-2.77%)
CGC   7.64 (-1.80%)
MU   90.00 (-3.09%)
GE   100.62 (-2.21%)
T   27.28 (-0.11%)
F   22.45 (-7.92%)
DIS   150.11 (-1.42%)
AMC   18.32 (-2.76%)
PFE   53.54 (-1.05%)
ACB   4.86 (-4.89%)
BA   217.08 (-3.52%)
NASDAQ:SLDB

Solid Biosciences Stock Forecast, Price & News

$1.38
-0.10 (-6.76%)
(As of 01/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.34
$1.47
50-Day Range
$1.38
$2.17
52-Week Range
$1.34
$11.58
Volume
2.61 million shs
Average Volume
1.27 million shs
Market Capitalization
$152.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.89
30 days | 90 days | 365 days | Advanced Chart
Receive SLDB News and Ratings via Email

Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Solid Biosciences logo

About Solid Biosciences

Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy (DMD). It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.

Headlines

REGENXBIO (RGNX) DMD Gene Therapy Gets Orphan Drug Status
November 23, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SLDB
Fax
N/A
Employees
70
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.56 per share

Profitability

Net Income
$-88.29 million
Pretax Margin
-716.04%

Debt

Price-To-Earnings

Miscellaneous

Free Float
82,832,000
Market Cap
$152.21 million
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
1/19/2022
Next Earnings (Estimated)
3/21/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.36 out of 5 stars

Medical Sector

221st out of 1,415 stocks

Biological Products, Except Diagnostic Industry

37th out of 206 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Solid Biosciences (NASDAQ:SLDB) Frequently Asked Questions

Is Solid Biosciences a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Solid Biosciences stock.
View analyst ratings for Solid Biosciences
or view top-rated stocks.

How has Solid Biosciences' stock price been impacted by COVID-19 (Coronavirus)?

Solid Biosciences' stock was trading at $3.14 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SLDB shares have decreased by 56.1% and is now trading at $1.38.
View which stocks have been most impacted by COVID-19
.

When is Solid Biosciences' next earnings date?

Solid Biosciences is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for Solid Biosciences
.

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc. (NASDAQ:SLDB) released its earnings results on Tuesday, November, 2nd. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.04. The business earned $3.54 million during the quarter, compared to the consensus estimate of $3.30 million.
View Solid Biosciences' earnings history
.

What price target have analysts set for SLDB?

6 brokerages have issued 1-year target prices for Solid Biosciences' shares. Their forecasts range from $6.00 to $17.00. On average, they anticipate Solid Biosciences' stock price to reach $10.17 in the next year. This suggests a possible upside of 636.7% from the stock's current price.
View analysts' price targets for Solid Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Solid Biosciences' key executives?

Solid Biosciences' management team includes the following people:
  • Ilan Ganot, President, Chief Executive Officer & Director
  • Joel Schneider, Chief Operating Officer
  • Stephen J. DiPalma, Chief Financial Officer & Treasurer
  • Carl Morris, Chief Scientific Officer
  • Roxana Donisa Dreghici, Senior Vice President-Clinical Development

What other stocks do shareholders of Solid Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include Selecta Biosciences (SELB), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Cidara Therapeutics (CDTX), SCYNEXIS (SCYX), Verastem (VSTM) and Agile Therapeutics (AGRX).

When did Solid Biosciences IPO?

(SLDB) raised $130 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers.

What is Solid Biosciences' stock symbol?

Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB."

How do I buy shares of Solid Biosciences?

Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Solid Biosciences' stock price today?

One share of SLDB stock can currently be purchased for approximately $1.38.

How much money does Solid Biosciences make?

Solid Biosciences has a market capitalization of $152.21 million. The company earns $-88.29 million in net income (profit) each year or ($0.83) on an earnings per share basis.

How many employees does Solid Biosciences have?

Solid Biosciences employs 70 workers across the globe.

What is Solid Biosciences' official website?

The official website for Solid Biosciences is www.solidbio.com.

Where are Solid Biosciences' headquarters?

Solid Biosciences is headquartered at 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139.

How can I contact Solid Biosciences?

Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at (617) 337-4680.


This page was last updated on 1/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.